People in the News

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Mar 02, 2018

Kim Albizati

Molecular Assemblies has appointed Kim Albizati as VP of chemistry and biochemistry. Prior to Molecular Assemblies, Albizati served senior direcctor of chemistry, manufactoring, and controls at Dart Neuroscience. In addition, Albizati has served as executive director of chemistry at Agouron and leadership positions at Pfizer. 

Mar 01, 2018

Guillaume Bouhours

BioMérieux has appointed Guillaume Bouhours as corporate vice-president, CFO, and a member of its executive committee. He replaces Claire Giraut, who is retiring, and will head the firm's finance, purchasing, and information systems departments. Bouhours was previously CFO at Faiveley Transport, a railway equipment manufacturer based in France.

Mar 01, 2018

Jeffrey Mitchell

LexaGene Holdings has appointed Jeffrey Mitchell as its chief financial officer effective immediately. 

Mitchell has more than two decades of financial and SEC experience, LexaGene said. Before joining the firm, he served in positions of increasing responsibility for Palomar Medical Technologies, including controller, director of finance, and supervisor of public-company financial reporting, audits, and financial planning and analysis.

He replaced Zula Kropivnitski.

Mar 01, 2018

Frank Williams

Frank Williams, cofounder and CEO of value-based care management company Evolent Health, has been named to the board of directors of precision oncology technology vendor Syapse. Syapse said that Williams, a former CEO of the Advisory Board Company, will be able to offer strategic advice as the company expands its reach. Since late November, Syapse has raised $30 million in new investment, hired a new VP of oncology, entered into a partnership with Roche, and entered the Asian market

Feb 28, 2018

Jon Faiz Kayyem

GenMark Diagnostics' Founder Jon Faiz Kayyem is transitioning from his position as head of R&D to become a technical and strategic advisor to its management team and board of directors. Kayyem is the inventor of the firm's eSensor electronic detection technology and led the development of its ePlex multiplex platform. Kayyem noted during a company presentation Tuesday that he will now "endeavor to add value in new ways beyond ePlex."

Feb 23, 2018

Gianluca Pettiti

Gianluca Pettiti has become president of the biosciences business of Thermo Fisher Scientific's Life Sciences Solutions segment. Previously, he was the company's president in Greater China. He joined the firm in 2006 as senior manager of financial planning and analysis for Applied Biosystem's Europe, Middle East, and Africa region. He later became EMEA finance director and then president of Latin America operations at Life Technologies. Pettiti holds a master's degree in management and financial engineering from the Polytechnic University of Turin in Italy.

Feb 22, 2018

Clive Brown

Clive Brown's appointment as director of Oxford Nanopore Technologies ended on Jan. 25, the company said in a filing this week. He is the firm's chief technology officer. Brown was appointed as a company director in September 2017.

Feb 21, 2018

Anthony Mattacchione, Gerald Herman

Bruker said that Anthony Mattacchione will resign as chief financial officer and senior VP, effective Mar. 16, 2018. Mattacchione has accepted a position as CFO of Albany Molecular Research, commencing in April 2018. Gerald Herman, currently vice president and corporate controller at Bruker, will also serve as Bruker's principal accounting officer, effective immediately. Herman joined the firm in 2016 as VP and corporate controller. Prior to that, he served as corporate VP of clinical operations of Parexel from 2014 to February 2016, and before that, corporate VP of Parexel from 2008 to 2013. Herman has also served as VP-corporate controller of Presstek.

Feb 20, 2018

Robert Hugin

Robert Hugin has resigned as a director at Danaher, following his decision to run for the US Senate representing New Jersey. He will run as a Republican against Sen. Robert Menendez, a Democrat. According to Politico, Hugin is a supporter of President Donald Trump. He was previously the executive chairman of Celgene before retiring from that position in January, and he was CEO of the company from June 2010 to March 2016.

Feb 16, 2018

John Goetz

John Goetz, the executive vice president and chief operating officer of Bio-Rad Laboratories, will retire and resign from his position effective March 30, 2018, but will remain available for consultation after his employment ends if a successor has not yet been named. Goetz has been with Bio-Rad for more than 40 years and was named COO in 2014. 

Feb 16, 2018

Shawn Clairmont

Codexis has appointed Shawn Clairmont senior director of molecular diagnostics. She will be responsible for commercial activities related to the firm's molecular diagnostics enzyme product line in development. Clairmont previously served as chief operating officer of BRIDGenomics. She was with Qiagen for eight years, most recently in the global advanced molecular pathology team as director of sales in America, and was also technical marketing representative and account manager at BioArray Solutions (now part of Immucor).

Feb 13, 2018

Michael Pellini

Adaptive Biotechnologies announced that former Foundation Medicine CEO Michael Pellini has joined its board. Pellini is currently chairman of Foundation Medicine's board, and is a managing partner of life science venture capital firm Section 32. He previously was president and chief operating officer of Clarient, which was acquired by GE Healthcare in 2010. He currently also serves on the boards of Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, and the Mission Hospital Foundation. 

Feb 09, 2018

Eutillio Buccilli, Paul Kasian

Genetic Technologies, a Melbourne, Australia-based molecular diagnostics company, said this week that Eutillio Buccilli will step down as CEO. Buccilli joined the company in June 2014 as CFO and was appointed CEO in February 2015. Paul Kasian has been appointed interim CEO while the company undertakes an executive search for a permanent CEO.

Feb 07, 2018

Alberto Gutierrez

Alberto Gutierrez has joined NDA Partners as an expert consultant. The company provides consulting services in product development and regulation of medical products. Gutierrez is the former director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health. He spent 25 years at the agency before leaving last September

Feb 05, 2018

Panna Sharma

Cancer Genetics announced that its CEO Panna Sharma will be stepping down as president, director, and CEO of the firm. The company’s board has appointed current COO John Roberts as the interim CEO. Sharma will provide consulting services during the transition period. 

Feb 02, 2018

Matthew McGrew, Daniel Comas

Danaher announced Matthew McGrew will become the firm's CFO, effective Jan. 1, 2019. He will replace Daniel Comas, who will continue as an executive vice president and a member of the Office of the Chief Executive as he begins a gradual transition to retirement. McGrew joined Danaher in 2004 as director M&A Finance. He currently is Group CFO of Danaher's Diagnostics and Dental platforms. Comas has been with Danaher since 1991 and became its CFO in 2005. 

Feb 01, 2018

Jonathan Sheldon

Qiagen has hired Jonathan Sheldon as senior vice president in charge of the company's bioinformatics business, to fill the vacancy created when Laura Furmanski left late last year. Sheldon, who also joins Qiagen's executive committee, most recently had been in charge of health sciences at Oracle. He previously started and directed the bioinformatics group at Roche (UK) Pharmaceuticals.

Jan 30, 2018

Mike Harkins, Katherine Atkinson

Edico Genome has named Mike Harkins as vice president of sales and Katherine Atkinson as VP of business development. Together, they will seek to expand the global market for the DRAGEN bio IT platform, the company said. Harkins previously led bioproduction sales at Thermo Fisher Scientific, while Atkinson most recently was commercial director of global channel partners for Illumina.

Jan 25, 2018

David Atkins

David Atkins has been named CEO of Congenica, a Cambridge, England-based maker of clinical genomics interpretation software. Atkins will lead Congenica as it looks to expand to the US and Asia, the company said. He previously served as CEO of Synevo, a chain of clinical diagnostic laboratories in Germany and Eastern Europe. With the hiring of Atkins, interim CEO Nick Lench resumes his full-time duties as chief operating officer. Cofounder and former CEO Tom Weaver remains on the Congenica board.

Jan 25, 2018

Greg Dale

LexaGene announced today that it has appointed Greg Dale as VP of product development and manufacturing. Dale previously served as VP of product development, manufacturing, and quality at Emulate. Prior to Emulate, Dale served as general manager and senior director of NGS engineering at Qiagen. 

Jan 24, 2018

Nalini Murdter

JSR Life Sciences has appointed Nalini Murdter as president and CEO of MBL International (MBLI), a JSR subdivision that provides products for life sciences research and clinical diagnostics, specializing in reagents and assays for detecting biomarkers and analyzing disease pathways. Murdter previously served as vice president of commercial operations and business development at MBLI, and managing director of the diagnostics and research products division at JSR. She was previously chief business offices a NanoString Technologies, and held several senior management positions in business development, strategy, and marketing at Agilent Technologies.

Jan 19, 2018

Tadd Lazarus

Clinical Genomics has appointed Tadd Lazarus as chief medical officer. Lazarus most recently served as senior vice president and chief medical officer for Luminex. He also served as chief medical officer and head of medical and scientific affairs, reimbursement, and public policy at Qiagen from 2013 to 2016. Lazarus also was previously employed by Gen-Probe (now Hologic) as chief medical officer and VP of clinical affairs. He began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as director of medical and scientific affairs, and then as the North American medical director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology businesses.

Jan 18, 2018

Dow Wilson

Varian Medical Systems CEO Dow Wilson has been elected to the board of Agilent Technologies, effective March 20. Wilson has been CEO of Varian Medical since 2012. Before being appointed CEO, he was the firm's chief operating officer and executive vice president. Prior to that, he was president of Varian Medical's Oncology Systems business. He previously spent 19 years at GE Healthcare and eventually became CEO of GE's Healthcare Information Technology unit. 

Jan 18, 2018

Douglas Sites

Precipio has appointed Douglas Sites to the newly created position of vice president of sales, where he will be responsible for leading sales of the firm's cancer diagnostic services to oncologists and hospitals. The company also said that it plans to triple the size of its sales force in 2018, focusing first on small to midsize oncology practices and hospitals. Sites has spent the last 20 years in life sciences and cancer diagnostics, including roles as director of sales at Plus Diagnostics and VP of sales at Asuragen. 

Pages

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.